Print Friendly, PDF & Email

Author Archives: kkc

Valerie V., Transsphenoidal Pituitary Surgery

I’m a 70-year-old retired female from North Carolina (just outside Asheville), and this is my Cushing’s story. Over the last 2 years, my husband noticed a change in my behavior, as well as some physical changes. We both thought these health issues were related to diabetes 2 (non-insulin) which I’ve had for 6 years.Continue Reading

Zoann M., Medication Induced Cushing’s

My Life with Asthma: Medication Induced Cushing’s Syndrome: My journey to Cushing’s began in gym class. I was 12 years old and was assigned to run the 400-meter sprint in a track meet. This wasn’t a great fit for someone with coughing fits when I ran. While practicing, I collapsed from coughing and passed out. My mother and doctor suspected a heart issue because I didn’t have wheezing, a classic asthma symptom.Continue Reading

Vascular Health in Patients in Remission of Cushing’s Syndrome is Comparable with that in Healthy People when Comorbidities are Treated Adequately

Many patients are asking if they have a higher cardiovascular risk as a result of Cushing’s. This article will focus on this question in a group of patients in long-term remission of Cushing’s syndrome.Continue Reading

Are You Living with Endogenous Cushing’s Syndrome?

Now looking for volunteers to participate in SONICS, a clinical study for an investigational drug (COR-003). The purpose of the study is to test the safety and efficacy of COR-003 in the treatment of endogenous Cushing’s syndrome. This study is open-label, which means both the health providers and the participants in the study are aware of the drug or treatment being given. Information from this study will also help doctors learn more about COR-003 in treating endogenous Cushing’s syndrome.Continue Reading

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing’s Syndrome

“A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing’s Syndrome” is a study for adults with Cushing’s Syndrome and is sponsored by Millendo Therapeutics, Inc. This study will evaluate the efficacy and safety of ATR-101 which is an oral study medication for the treatment of endogenous Cushing’s syndrome. The studyContinue Reading

Connect


Contact Us